Friday, 23 June 2017

Merck’s Keytruda prolong life in lung cancer study

According to report, Merck & Co's
approved Keytruda lung cancer
treatment is said to provided superior
overall survival to chemotherapy.

This is confirmed
in a late-stage study of patients
with advanced disease whose
tumors produce a protein called
PD-L1 associated with increased
risk of the disease.

No comments:

Post a Comment

More exercise leads to more youthful arteries

According to US research exercising two to three times a week (30 minutes per session) over a lifetime led to more youthful middle-sized ar...